LAKEWOOD, Colo. – October 5, 2023 – Terumo Blood and Cell Technologies today announced the launch of a study with BioCentriq® to generate publicly available CAR-T cell manufacturing data using Terumo BCT's cell and gene therapy manufacturing platforms.
The study aims to generate open, accessible data on CAR-T cell manufacturing processes using Terumo BCT's automated platforms, helping to advance industry-wide understanding of process optimization for cell therapy manufacturing.
"By generating and sharing this data publicly, we hope to accelerate innovation across the cell and gene therapy industry," said a Terumo Blood and Cell Technologies representative. "This collaboration with BioCentriq reflects our commitment to advancing the field through open, collaborative research."
The resulting data set is intended to serve as a resource for researchers and manufacturers working to optimize CAR-T cell therapy production processes.
About Terumo Blood and Cell Technologies
Terumo Blood and Cell Technologies, a Terumo group company, is a global leader committed to providing high-quality products and services for blood and blood component collection, and for the production of biotherapies, including cell and gene therapies. Together with our partners and customers, we envision and advance a world where blood and cell technologies contribute to the health and well-being of all people.
